KPV On 23 July 2026, PCAC voted to recommend adding KPV to the 503A Bulks List, in opposition to the FDA staff review, which had recommended against listing
The short answer: yes, but with a few important caveats
They saturate receptors all day, drive hunger way down, and average 15 percent weight loss in a year (CSPI)
Offering both injectable and oral options, semaglutide works by mimicking the GLP-1 hormone, reducing appetite, and promoting sustainable weight loss
In fact, existing research suggests that adhering to a high-protein diet while undergoing weight loss can help mitigate the loss of lean body tissue
Conclusion Adjusting your weight loss goals while using GLP-1 medications isnt something you do just once its a continuous process